| Autor: |
Surbhi Sidana, Andriyana K. Bankova, Hitomi Hosoya, Shaji K. Kumar, Tyson H. Holmes, John Tamaresis, Anne Le, Lori S. Muffly, Sofia Maysel-Auslender, Laura Johnston, Sally Arai, Robert Lowsky, Everett Meyer, Andrew Rezvani, Wen-Kai Weng, Matthew J. Frank, Parveen Shiraz, Holden T. Maecker, Ying Lu, David B. Miklos, Judith A. Shizuru |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2044-5385 |
| DOI: |
10.1038/s41408-024-01152-1 |
| Popis: |
Abstract MGTA-145 or GROβT, a CXCR2 agonist, has shown promising activity for hematopoietic stem cell (HSC) mobilization with plerixafor in pre-clinical studies and healthy volunteers. Twenty-five patients with multiple myeloma enrolled in a phase 2 trial evaluating MGTA-145 and plerixafor for HSC mobilization (NCT04552743). Plerixafor was given subcutaneously followed 2 h later by MGTA-145 (0.03 mg/kg) intravenously with same day apheresis. Mobilization/apheresis could be repeated for a second day in patients who collected |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink